Browsing Tag
Bemnifosbuvir
1 post
Phase 3 hepatitis C win fails to lift Atea stock against Gilead’s Epclusa
Atea’s eight-week hepatitis C regimen met Phase 3 endpoints against Epclusa, but $AVIR fell as investors questioned its commercial edge.